MIRM Mirum Pharmaceuticals
- 29.025
- -0.225-0.77%
Mirum Pharmaceuticals News
Morgan Stanley Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $57
JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating
Stifel Reiterates Buy on Mirum Pharmaceuticals, Maintains $48 Price Target
Mirum Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating
Mirum Pharmaceuticals Analyst Ratings
Mirum Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Mirum Pharmaceuticals (MIRM) and IDEAYA Biosciences (IDYA)
Mirum Pharmaceuticals Analyst Ratings
Positive Outlook for Mirum Pharmaceuticals With Buy Rating Amid Upcoming Catalysts and Robust Financials
Citibank: Maintains the Mirum Pharmaceuticals (MIRM.US) rating, adjusted from buy to buy rating, and adjusted the target price from $37.00 to $38.00.
Mirum Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Beam Therapeutics (BEAM) and Mirum Pharmaceuticals (MIRM)
HC Wainwright & Co. : The Mirum Pharmaceuticals (MIRM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $58.00.
Mirum Pharmaceuticals Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Mirum Pharmaceuticals, Maintains $58 Price Target
Mirum Pharmaceuticals (MIRM.US) was first covered by Stifel, giving it a buy rating, with a target price of $48.00.
Mirum Pharmaceuticals Analyst Ratings
Stifel Initiates Coverage On Mirum Pharmaceuticals With Buy Rating, Announces Price Target of $48
Analysis
Price Target
No Data
